Stay updated on Asciminib Combo with Imatinib in CML-CP Clinical Trial
Sign up to get notified when there's something new on the Asciminib Combo with Imatinib in CML-CP Clinical Trial page.

Latest updates to the Asciminib Combo with Imatinib in CML-CP Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe page’s revision label has been updated from v3.5.3 to v3.5.4, indicating a minor update to the documentation/versioning of the study page. This reflects an administrative update rather than any change to the trial data or details.SummaryDifference0.0%

- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedTaoyuan District, Taiwan, 33305 was replaced with Taoyuan, Taiwan, 33305 in the Locations section. This updates the listed site to reflect the correct municipality.SummaryDifference0.0%

- Check40 days agoChange DetectedThe study record has been updated to reflect an additional **asciminib 80 mg single-agent cohort (ASAC)** added after the primary analysis, alongside the ongoing randomized add-on/switch/continue arms. Corresponding **primary/secondary outcome measure definitions** and related endpoint timing (e.g., **MR4.5 rates at 48 and 96 weeks** and related analyses) were also updated to include this single-agent evaluation.SummaryDifference4%

- Check47 days agoChange DetectedRevision added: v3.5.2. Revision removed: v3.5.0.SummaryDifference0.0%

- Check76 days agoChange DetectedPage revision tag updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check90 days agoChange DetectedRevision: v3.4.3 added and Revision: v3.4.2 removed.SummaryDifference0.0%

Stay in the know with updates to Asciminib Combo with Imatinib in CML-CP Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Asciminib Combo with Imatinib in CML-CP Clinical Trial page.